If you’re on social media, you may feel bombarded by influencers promoting peptides for a range of ailments so broad it almost seems like a brand-new trend. But peptide-based therapies actually date back to 1922, when insulin was first administered to treat diabetes. But it wasn’t until semaglutide (better known as Ozempic) entered the market that peptides truly captured public attention. In today’s episode, we explore how what chemists and other scientists learned from insulin paved the way for the remarkable effectiveness of GLP-1 drugs, and how treatments originally developed for diabetes are now being used to address obesity, substance use, and more.
Podden och tillhörande omslagsbild på den här sidan tillhör
American Chemical Society. Innehållet i podden är skapat av American Chemical Society och inte av,
eller tillsammans med, Poddtoppen.